Management of Toxicities After Chimeric Antigen Re-ceptor T-cell Therapy and Progress of Bridging Therapy in Lymphoma Patients
10.11735/j.issn.1004-0242.2025.09.A007
- VernacularTitle:淋巴瘤患者CAR-T治疗后毒副反应的管理与桥接治疗的研究进展
- Author:
Zhangyan WANG
1
;
Huangming HONG
;
Tongyu LIN
Author Information
1. 电子科技大学医学院,四川省肿瘤医院·研究所,四川 成都 610041
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor T-cell therapy;
lymphoma;
toxicities;
cytokine release syndrome;
bridging therapy
- From:
China Cancer
2025;34(9):734-741
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell(CAR-T)therapy,as a revolutionary immunotherapy,has achieved significant clinical efficacy in the treatment of hematologic malignancies in recent years.However,its clinical application remains limited by associated toxicities.Bridging therapy,as a supplementary antitumor treatment administered between leukapheresis and CAR-T cell infusion,reduces tumor burden and modulates the immune microenvironment through chemotherapy,radio-therapy,targeted therapy,and immunotherapy.It not only delays disease progression but also sig-nificantly influences the toxicities associated with subsequent CAR-T therapy.This paper reviews the main types of toxicities and management strategies of CAR-T therapy,and analyzes the role of bridging therapy in managing these toxicities,conducting an in-depth analysis of the potential mechanisms by which different bridging therapy modalities influence these toxicities,to provide scientific basis and practical guidance for the clinical application of CAR-T therapy.
